Rapamycin and Alzheimer's disease: Time for a clinical trial?

Matt Kaeberlein, Veronica Galvan

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations


The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.

Original languageEnglish (US)
Article numbereaar4289
JournalScience translational medicine
Issue number476
StatePublished - Jan 23 2019

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Rapamycin and Alzheimer's disease: Time for a clinical trial?'. Together they form a unique fingerprint.

Cite this